BriaCell Therapeutics Corp.
BCTXW · NASDAQ
10/31/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | -0.00 | -0.01 |
| FCF Yield | -6,770.80% | -11,097.17% | -1,598,120.71% | -195.82% |
| EV / EBITDA | 0.32 | -0.56 | 2.02 | 0.28 |
| Quality | ||||
| ROIC | -84.45% | -49.03% | -49.94% | -173.47% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.92 | 1.00 | 1.15 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 6.21% | -13.54% | -20.99% | 14.88% |
| Safety | ||||
| Net Debt / EBITDA | 0.33 | -0.57 | 2.02 | 0.70 |
| Interest Coverage | 0.00 | 229.43 | -171.13 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -11,154.69 | -10,752.27 | 0.00 |